Introduction
Gaucher disease type 1 is an autosomal recessive disorder caused by reduced activity of the lysosomal enzyme acid β-glucosidase leading to pathologic accumulation of glucosylceramide, primarily in macrophages. Clinical manifestations include hepatosplenomegaly, anemia, thrombocytopenia, and skeletal disease [1] . Two treatment approaches exist: intravenous enzyme therapy using human recombinant acid βglucosidase and oral substrate reduction therapy. Enzyme therapy augments the ability of macrophages to break down substrate. Currently, three enzyme therapies are available for the treatment of Gaucher disease type 1: imiglucerase (Cerezyme®, Sanofi Genzyme, first available in 1994, produced in a Chinese hamster ovary cell line), velaglucerase alfa (VPRIV®, Shire Pharmaceuticals, first available in 2010, produced in a human fibrosarcoma cell line), and taliglucerase alfa (Elelyso®, Pfizer/Protalix, first available in 2012, produced in a genetically modified carrot cell line). In addition to their different production platforms, these human recombinant acid β-glucosidase products have minor structural differences and, thus, are not considered biosimilar agents by the United States Food and Drug Administration [2] .
Substrate reduction therapy selectively inhibits glucosylceramide synthase, thereby slowing the production of glucosylceramide [3] . Currently, two such therapies are available: miglustat (Zavesca®, Actelion Therapeutics), a second-line therapy for adults with Gaucher disease type 1 who are not candidates for enzyme therapy, and eliglustat (Cerdelga®, Sanofi Genzyme), which was approved in the United States in 2014 and the European Union in 2015 as a first-line treatment for adults with Gaucher disease type 1 who are poor, intermediate, or extensive CYP2D6 metabolizers (≈ 95% of patients [4] ). Clinical trials of eliglustat in adults with Gaucher disease showed hematologic, 
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Molecular Genetics and Metabolism Reports j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y m g m r visceral, and skeletal improvements in treatment-naïve patients [5] [6] [7] [8] [9] and, in patients previously treated with intravenous enzyme therapy, the drug maintained disease stability [10] . With up to five therapeutic options for Gaucher disease, it is important for clinicians to understand the potential implications of switching from one treatment to another. Several switch studies have assessed the outcome of switching from imiglucerase (the historic standard of care) to velaglucerase alfa [11] , taliglucerase alfa [12] , or miglustat [13] . The eliglustat ENCORE study (NCT00943111, sponsored by Sanofi Genzyme) assessed the outcome of patients switching from enzyme therapy (imiglucerase or velaglucerase alfa) to eliglustat. The primary analysis of this imiglucerase-controlled study found eliglustat noninferior to imiglucerase in maintaining clinical stability for 12 months [10] . Since a subset of patients in ENCORE were being treated with velaglucerase alfa at baseline, this trial also offers the opportunity to perform a post-hoc analysis of two other switch populations that have not been evaluated to date: patients switching from velaglucerase alfa to eliglustat and patients switching from velaglucerase alfa to imiglucerase.
Patients and methods
The randomized, multinational, open-label Phase 3 ENCORE trial evaluated 159 adults with confirmed acid β-glucosidase deficiency who had achieved the following pre-specified therapeutic goals after ≥ 3 years of enzyme therapy: hemoglobin concentration ≥ 11g/dL (women), ≥12 g/dL (men); platelet count ≥100 × 10 9 /L, spleen volume b10 multiples of normal (MN); liver volume b1.5 MN; and no bone crisis or symptomatic bone disease within the last year [10] . Patients were stratified on the basis of their previous enzyme therapy dose (b35 units/ kg/2 weeks or ≥35 units/kg/2 weeks) and randomized 2:1 to receive either oral eliglustat (n = 106) or imiglucerase infusions (n = 53) for 12 months.
The composite primary efficacy endpoint was the percentage of patients meeting all four pre-specified stability parameters. In relation to baseline measurements, hemoglobin concentration could not decrease by N 1.5 g/dL, platelet count could not decrease by N25%, and spleen and liver volumes could not increase by N25% and N20%, respectively [10] . As this was a non-inferiority study, efficacy analyses were carried out on the 99 eliglustat and 47 imiglucerase patients in the perprotocol population. Secondary endpoints were the percentage of patients who met the stability criterion for each individual component of the primary endpoint (hemoglobin concentration, platelet count, spleen volume, and liver volume) [10] .
This post-hoc analysis examined efficacy and safety in the subset of ENCORE patients whose enzyme therapy at baseline was velaglucerase alfa. As in the primary analysis, efficacy analyses were done on the per-protocol population and safety data were evaluated in all treated patients; however, results are descriptive only as the trial was not designed to compare velaglucerase alfa with eliglustat or imiglucerase.
Results
Of the 159 patients who participated in ENCORE, 30 were receiving velaglucerase alfa at baseline and were randomized to eliglustat (n = 22) or imiglucerase (n = 8). Baseline characteristics of these subgroups were similar to the two treatment arms of ENCORE except for a higher proportion of females to males in the subgroup of patients who transitioned from velaglucerase alfa to imiglucerase (Table 1) [10] . Since all patients had to have received enzyme therapy for ≥3 years before study entry and velaglucerase alfa became available b3 years before the trial began, all patients who transitioned from velaglucerase alfa had previously received imiglucerase (mean duration of prior imiglucerase treatment for the entire trial population was 10 years) [10] . All but two of the 30 patients were included in the per-protocol population; both exclusions were in the eliglustat groupone patient withdrew (see below) and the other was excluded because of b80% dosing compliance ( Fig. 1) .
Hemoglobin concentration, platelet count, spleen volume, and liver volume remained stable among patients transitioned from velaglucerase alfa in both the eliglustat and imiglucerase trial arms over 12 months (Fig. 2) . Overall, 18/20 (90%) velaglucerase alfa to eliglustat patients and 7/8 (88%) velaglucerase alfa to imiglucerase patients met the primary composite endpoint. These numbers were similar in the intent-to-treat population; 19/22 (86%) velaglucerase alfa to eliglustat patients and 7/8 (88%) velaglucerase alfa to imiglucerase patients met the primary composite endpoint.
The three patients in the per-protocol population who did not meet the composite endpoint each missed by a single criterion: hemoglobin concentration (eliglustat patient), platelet count (eliglustat patient), and liver volume (imiglucerase patient). In all three cases, there was no clinical deterioration despite the change from baseline, and patients maintained absolute values for these endpoints that remained within therapeutic goals for enzyme therapy as defined by Pastores et al. [14] . With respect to individual stability goals (secondary endpoints), in the eliglustat arm 19/20 (95%) patients met the stability criterion for hemoglobin and platelet counts, and 20/20 (100%) for spleen and liver volumes. In the imiglucerase arm, 8/8 (100%) patients met stability criteria for hemoglobin, platelets, and spleen volume and 7/8 (83%) for liver volume. These efficacy results are consistent with those observed in the primary analysis of the ENCORE trial, in which 84/99 (85%) eliglustattreated patients and 44/47 (94%) imiglucerase-treated patients met the primary composite endpoint, with the lower bound of the 95% CI of the between-group difference (− 17.6%) falling within the prespecified 25% threshold for non-inferiority [10] .
As expected in a population with stable disease on enzyme therapy, mean baseline bone mineral density scores for both lumbar spine and femur were in the reference (normal) range. Mean bone marrow burden scores were in the moderate infiltration range. As was reported in the full trial population, patients transitioned from velaglucerase alfa had stable bone measures after 12 months [10]. The frequency and severity of adverse events in the patients transitioned from velaglucerase alfa were consistent with those reported in the full trial population [10] . Most adverse events were mild or moderate in severity, and there were no treatment-related serious adverse events ( Table 2 ). In the 22 patients randomized to eliglustat, treatment-related events occurring in ≥ 2 patients were diarrhea, fatigue, headache, pain in extremity, palpitations, and throat irritation; each occurred in two (9%) patients. Four serious adverse events occurred: appendicitis, syncope, ischemic colitis, and uterine leiomyoma. All were considered unrelated to treatment and none resulted in study withdrawal. The one withdrawal was due to an adverse event (palpitations) that was moderate in severity and considered possibly related to eliglustat; the event resolved without treatment. Among the eight patients who were transitioned from velaglucerase alfa and randomized to imiglucerase, two events (anxiety and back pain) in two patients were considered related to treatment, and there were no serious adverse events. After the 12-month primary analysis period, 29/30 (97%) patients who transitioned from velaglucerase alfa entered the openlabel extension study.
Discussion and conclusions
The data from this post-hoc analysis of a clinical trial subpopulation suggest that eliglustat and imiglucerase were well-tolerated and maintained clinical stability in adults (n = 30) with Gaucher disease type 1 who were previously treated with velaglucerase alfa. Study limitations include limited number of patients receiving either maintenance therapy with eliglustat (n = 20, 1 withdrawn, 1 excluded because of dosing b80% as per protocol) and imiglucerase (n = 8). Safety and efficacy in these patients were consistent with what was observed for the entire ENCORE trial population.
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